Once approved as a cancer-drug, it can potentially change the lives of many women patients all over the world.
PARP inhibitors are also believed to treat common types of breast cancer.
New Treatment for Breast Cancer patients
What are PARP inhibitors?
PARP (Poly ADP ribose polymerase) inhibitors repair the DNA structure in faulty genes and suppress the tumour. Olaparib is a PARP inhibitor that is used to treat ovarian cancer.
The drug's effect on cancer
More types of breast cancer can now be treated by PARP inhibitors.
These forms of the cancer are biochemically comparable to the rare cases of mutation of BRCA genes. Without mutation, BRCA1 and 2 genes are tumour suppressing genes or caretaker genes.
If the clinical trials are successful, the drug can also be helpful in treating other forms of cancer like prostate cancer.
Love Tech news?
Stay updated with the latest happenings.
Clinical trials of the drug
These formulations are available only for clinical trials among women in UK.
It may take some time for the PARP inhibitors to be approved as cancer drugs.
The results have so far been effective and their approval could mean efficient cancer treatment for one out of five women affected by breast cancer.
Population and Breast Cancer
Currently, approximately 12% (1 out of 8) women in US and 15% in UK are likely to develop invasive breast cancer in their lifetime.
Women in Europe mainly Belgium, Denmark and UK, North America and Oceania are mostly affected by breast cancer.
HRDetect- a computer software helps in detecting genetic errors causing breast cancer and helps in the long run.
NASA's tests show life could be possible on Mars
Gmail rolls out new feature to send and request money